Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment

Chen, Jiajia; Hu, Chenxia; Chen, Lijun; Tang, Lingling; Zhu, Yixin; Xu, Xiaowei; Chen, Lu; Gao, Hainv; Lü, Xiaoqing; Yu, Liang; Dai, Xiahong; Xiang, Charlie

doi:10.1016/j.eng.2020.02.006

Cited by 224 publications

(255 citation statements)

References 53 publications

Supporting

Mentioning

243

Contrasting

Unclassified

Order By: Relevance

“…2). Recently, the use of these cells in the clinical treatment of H5N1 viral infections that have similar effects on the lung has also been suggested [29]. In addition, recently a case study was reported in China on a female patient with an acute COVID19 syndrome that the results of laboratory tests and CT images provided extremely effective results after 21 days of treatment with umbilical cord MSCs.…”

Section: Msc Clinical Trials For Covid-19mentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Golchin

Seyedjafari

Ardeshirylajimi

2020

Stem Cell Rev and Rep

286

295

View full text Add to dashboard Cite

" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.

show abstract

Section: Msc Clinical Trials For Covid-19mentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Golchin

Seyedjafari

Ardeshirylajimi

2020

Stem Cell Rev and Rep

286

295

View full text Add to dashboard Cite

show abstract

“…In 2013-2014, 17 patients with H7N9 influenza were treated with mesenchymal stem cells (MSCs) and outcomes were compared to 44 controls. Higher survival rate was noted in the MSC group compared to controls (82.4% vs 45.5%, respectively) [12]. For COVID-19, MSCs were recently investigated in a small case series out of China, but only one patient was critically ill [26].…”

Section: Introductionmentioning

confidence: 99%

Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series

et al. 2020

View full text Add to dashboard Cite

There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 . Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients (n = 6; age range 19-75 years, 1 female) required ventilatory support (invasive mechanical ventilation, n = 5) with PaO 2 /FiO 2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43-2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89-1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26-0.82 × 10 3 / µl) but had increased in three of these five patients at last follow-up (range 0.23-1.02 × 10 3 /µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.

show abstract

“…only critically severe and/or severe patients or for the broader range of clinical presentations of COVID-19 respiratory infection.A second recently published study evaluated MSC administration in patients with H7N9 influenza virus respiratory infections during the 2013-2014 outbreak in China [48]. In this study, 17 critically-ill patients with H7N9-induced ARDS received multiple IV administrations of menstrual blood-derived cells (10 6 cells/infusion in Plasmalyte) obtained from a single healthy donor and outcomes were compared to 44 comparably critically ill patients receiving standard antiviral and supportive therapies.…”

mentioning

confidence: 99%

Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19

et al. 2020

View full text Add to dashboard Cite

Severe respiratory consequences of the COVID-19 pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with the acute respiratory distress syndrome (ARDS), although not as yet well studied in respiratory virusinduced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (Influenza strains H5N1 and H9N2)-induced lung injury, however, there are no available data in models of coronavirus respiratory infection.There are a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilize a range of different cell sources, doses, dosing strategies, and targeted patient populations. To provide a rationale strategy to maximize potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. These are presented along with consideration of current clinical investigations.

show abstract

Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment

Cited by 224 publications

References 53 publications

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series

Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19

Contact Info

Product

Resources

About